Catinazzo Thomas 4
4 · Relay Therapeutics, Inc. · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
Relay Therapeutics CFO Thomas Catinazzo Sells 17,717 Shares
What Happened
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (RLAY), sold 17,717 shares in an open-market transaction on March 9, 2026. The weighted average sale price was $10.06, producing total proceeds of approximately $178,233. The trades were executed under a Rule 10b5-1 trading plan adopted October 30, 2025.
Key Details
- Transaction type: Sale (Code S) executed in multiple open-market trades on 2026-03-09.
- Price: Weighted average $10.06; individual trade prices ranged from $9.77 to $10.35. (Reporting person can provide per-trade prices on request.)
- Proceeds: ~$178,233.
- Shares owned after transaction: Not specified in the provided filing summary.
- Footnotes: F1 = trade pursuant to 10b5-1 plan (10/30/2025). F2 = multiple trades, price range noted. F3 = filing references 13,075 shares underlying restricted stock units (included in reported ownership).
- Filing: Reported on Form 4 filed 2026-03-11 (filed promptly following the 3/9 transaction).
Context
Sales made under a pre-established 10b5-1 trading plan are typically routine and were planned in advance; they do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases generally carry more weight as a signal than routine insider sales.
Insider Transaction Report
Form 4
Catinazzo Thomas
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-09$10.06/sh−17,717$178,233→ 231,584 total
Footnotes (3)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $9.77 to $10.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Includes 13,075 shares underlying restricted stock units.
Signature
/s/ Soo-Yeun Lim, as Attorney-in-Fact|2026-03-11